A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea
Clinical trial NCT04036448 · COMPLETED
Trial details
- NCT number
- NCT04036448
- Sponsor
- Celgene
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2019-11-28
- Primary completion
- 2023-08-15
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.